Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Shareholder Meeting (November 2016)
27 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 25, 2016
Slide 1: AGM 25 November 2016: Phylogica Platforms Combining to Progress Commercialisation
For personal use only AGM 25 November 2016 PHYLOGICA PLATFORMS COMBINING TO PROGRESS COMMERCIALISATION Ms Stephanie Unwin Chair
Slide 2: Disclaimer
Disclaimer The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) For personal use only [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc
Slide 3: 2016 A Year of Strong Progress
For personal use only 2016 A YEAR OF STRONG PROGRESS Further validation of our FPP intracellular delivery technology platform § FPP-mediated delivery of protein cargoes is very rapid and efficient § Quantified approximate concentration of the protein delivered into the cell – far superior concentrat
Slide 4: Identified Phylomers as drug cargo; progress on internal discovery program
Identified Phylomers for use as the drug cargo itself § Internal iMYC cancer program continues to build an impressive proof of concept data For personal use only pack on the way to formal preclinical development in the second half of 2017 Progress on the internal discovery program § Narrowed the num
Slide 5: iMYC candidates
iMYC candidates § Performing well on a number of measures For personal use only § No evidence of FPP-mediated toxicity § Improvements in pharmacokinetics § Evidence of activity in two independent animal models of cancer even when administered intravenously
Slide 6: Building confidence in the iMYC program
Building confidence in the iMYC program § The iMYC program is our most advanced with entry into a formal pre-clinical program For personal use only planned for H2 2017 § Phylogica is planning to achieve substantial increases in the potency of both its lead FPP and its lead iMYC before further multi-
Slide 7: Progress on Collaborations
Progress on Collaborations § Since June we have signed three non-disclosure agreements with international For personal use only pharmaceutical companies to discuss elements of Phylogica’s technology portfolio. § Genentech are due to make a decision regarding licensing/extension of novel antimicrobia
Slide 8: Phylomer Platform
Phylomer Platform § The core intellectual property of Phylogica is our extensive library made up of protein For personal use only fragments expressed from the genetic material of micro-organisms (Phylomers) § For several years, our team of scientists, managers and advisers has been working hard to u
Slide 9: Platform continued
Platform continued § Phylogica has significantly expanded the landscape of druggable targets as well as For personal use only enhancing the specificity and sensitivity of these drug-target interactions § Searching through our extensive library to identify Phylomers that may be used as the drug cargo
Slide 10: 2016 summary
For personal use only 2016 summary § Shortlisted oncology drug candidates for lead optimisation – Potential for formal pre-clinical studies in second half of 2017 § FPP cell delivery system is showing excellent results and remains highly competitive – See the next presentation from Paul Watt, our Ch
Slide 11: Technology Overview and Update
For personal use only Technology Overview and Update Adjunct Professor Paul Watt Chief Scientific Advisor
Slide 12: Phylogica Value Creation Engines
For personal use only Phylogica Value Creation Engines § Discovery (Phylomers) § Delivery (FPPs) § Development (iMYCs) 12
Slide 13: Delivery: Functional Penetrating Phylomers FPPs
For personal use only DELIVERY: Functional Penetrating Phylomers “FPPs” 13
Slide 14: Biologics drugs are trapped within endosomes
Biologics drugs are trapped within endosomes and thus their therapeutic effects are constrained For personal use only Drug Drug Contact triggers Drug contacts cell Budding formation of endosomes membrane endosome Cell Membrane 80% of potential drug targets are inside cells Endosome BIOLOGICS? Drug B
Slide 15: Endosomal Escape Trap Assay identifies Phylomers
PYC’s Endosomal Escape Trap Assay identifies Phylomers that can liberate cargoes OUT of endosome For personal use only Biotin Tag Enzymatic Streptavin attachment Avitag Phylomer Phylomer Phylomer Release and Capture Trapped Phylomer Escaped Phylomer (Streptavidin Beads) + Cargo + Cargo § Rare Phylom
Slide 16: Phylomer FPPs can deliver a diverse range of biologics cargoes
Phylomer FPPs can deliver a diverse range of biologics cargoes into cells For personal use only Peptides ✔ Toxins ✔ FPP Scaffolds ✔ Enzymes ✔ Oligonucleotides ✔
Slide 17: FPPs deliver diverse cargoes - continued
Phylomer FPPs can deliver a diverse range of biologics cargoes into cells - continued § Examples of cargoes delivered with FPP01 or its derivatives For personal use only § FPP versatile enough to deliver multiple cargoes with diverse size and charges Cargo Class Cargo Size/Charge IC50* **MED Toxin /
Slide 18: Superior delivery of FPP vs. TAT
Further evidence for superior delivery of FPP vs. TAT: quantified delivery of larger (iMyc) cargoes Two distinct FPP-iMyc fusion proteins applied to mammalian cells for 60min For personal use only § § Assay that specifically quantifies the efficiency of cell entry & escape of iMyc from the endosome
Slide 19: Efficacy following intravenous delivery in EµMyc lymphoma model
Evidence of efficacy following intravenous delivery in EµMyc lymphoma model Mice injected daily with 40 nanomoles of Phylomer FPP-Omomyc fusion for 4 days For personal use only EuMyc cells/mouse (in 100uL PBS) At each time point: D0 D3 D4 D5 D6D7 D8Extract D9 spleen- 2 mice per group are cellsand at
Slide 20: FPPs – What we have now established
FPPs – What we have now established § Enables endosomal escape For personal use only § Compatible with wide range of cargoes § Outperforms other intracellular delivery technologies § Functional in multiple cell types § Viable manufacturing and strong IP Position § Better understanding of mechanism o
Slide 21: iMYC Program
For personal use only iMYC Program (FPP combined with iMYC cargo) 21
Slide 22: iMYC Program Development Timelines
For personal use only iMYC Program Development Timelines 22
Slide 23: Good progress with proof-of-concept discovery program
Good progress with proof-of-concept discovery program For personal use only 23
Slide 24: Summary
For personal use only SUMMARY 24
Slide 25: Multiple commercialisation opportunities for FPPs
For personal use only Multiple commercialisation opportunities for FPPs ‘Value Adding’ Improve delivery of existing or Commercial & Academic new drugs Collaborations Functional Penetrating Phylomers ‘Phylomer Therapeutics’ Fully integrated drug iMYC, STAT5 & delivery/discovery platform YB1 programs
Slide 26: Commercialisation Progress
Commercialisation Progress § Academic and Commercial Collaborations progressing For personal use only – Murdoch University – Oligonucleotides for Muscular Dystrophy – ONJCRI (formerly Ludwig Institute) – Myc and Bcl2/Mcl1 Bispecifics – Genentech – Next generation Antimicrobials – >5 active other (co
Slide 27: Thanks to our R&D team and shareholders
Thanks to our talented R&D team for their hard work and to our shareholders for support • Katrin Hoffmann, DRSO • Laura Florez For personal use only • Heique Bogdawa • Rob Dewhurst • Nadia Milech • Marie Scobie • Karen Kroeger • Richard Francis • Paula Cunningham • Leanne Neville • Tatjana Heinrich